Literature DB >> 15889354

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Daniel M Musher1, Saima Aslam, Nancy Logan, Srikanth Nallacheru, Imran Bhaila, Franziska Borchert, Richard J Hamill.   

Abstract

BACKGROUND: Clostridium difficile is a frequent cause of serious nosocomial infection. Earlier reports have suggested that treatment with metronidazole cured nearly 90% of patients, with only a modest rate of recurrence of infection. In recent years, the rate of response to treatment with this drug has appeared to be much lower.
METHODS: We undertook a prospective, observational study of 207 patients who were treated with metronidazole for C. difficile colitis.
RESULTS: A total of 103 patients (50%) were cured by the initial course of therapy and had no recurrence of disease. Forty-six patients (22%) continued to have symptoms of colitis for > or = 10 days despite treatment, and 58 (28%) responded initially but had a recurrence within the ensuing 90 days. The mortality rate among patients who developed C. difficile colitis was 27%, and it was higher among patients who did not respond fully to an initial course of therapy, compared with those who did (33% vs. 21%; P < .05).
CONCLUSIONS: Because of the relatively poor response to therapy, additional approaches to prevention and/or treatment of C. difficile colitis appear to be warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889354     DOI: 10.1086/430311

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  139 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

3.  Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Authors:  April Roberts; Joanna McGlashan; Ibrahim Al-Abdulla; Roger Ling; Harriet Denton; Steve Green; Ruth Coxon; John Landon; Clifford Shone
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 4.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

5.  Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.

Authors:  P Patrick Basu; Amreen Dinani; Krishna Rayapudi; Tommy Pacana; Niraj James Shah; Hemant Hampole; N V Krishnaswamy; Vinod Mohan
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

6.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

7.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 8.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

9.  Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.

Authors:  Andrada Seicean; Anca Moldovan-Pop; Radu Seicean
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.